Empagliflozin is a novel sodium glucose co-transporter-2 (SGLT-2) inhibitor, which is useful for improving glycaemic control in adults with type-2 diabetes mellitus.
The consideration includes Rs. 115 crore (on the date of signing) of cash and cash equivalents in the acquired business indicating an Enterprise Value of Rs. 1,885 crore
The integration and transition of the brands are expected to be completed by June 2022.
The appraisal of the applications has been carried out based on the ranking methodology laid down in the operational guidelines of the Scheme
The injunction order has been passed against Natco Pharma, Torrent Pharmaceuticals, Eris Lifesciences and Windlas Biotech
In India, MSD has signed non-exclusive licensing agreements with eight pharma companies.
Torrent Pharmaceuticals Limited has reported consolidated financial results for the period ended September 30, 2021
Vikas Lifecare has already paid Rs. 25 million to the Advik bankers till date and the remaining amount shall also be paid within July 2021, making Advik a debt free company
The agreement will help ensure wider reach and access to patients in India
NPPA also fixed retail price of 76 new drugs in the meeting dated 10th March 2021 to be launched by existing manufacturers including off-patent Anti-diabetic drugs allowing due benefit of patent expiry to the patients.
Subscribe To Our Newsletter & Stay Updated
